Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2023 0 · FY2024 90 — 2-yr total 90
Abulpharm LLC is a Tbilisi-based pharmaceutical distributor and wholesaler set up with Turkish investment (~USD 2m), operating a pharmaceutical warehouse in the Gldani industrial zone with regional export activity, particularly to Russia.
| Line item | 2023 | 2024 | CAGR |
|---|---|---|---|
| 136,815 | 372,077 | +172.0% | |
| Total Non-Current Assets | 0 | 789 | |
| TOTAL ASSETS | 136,815 | 372,866 | +172.5% |
| 87,158 | 135,495 | +55.5% | |
| Total Non-Current Liabilities | 0 | 0 | |
| TOTAL LIABILITIES | 87,158 | 135,495 | +55.5% |
| 49,657 | 237,371 | +378.0% | |
| Balance Check (Assets - L&E) | 0 | 0 | |
| Debt analysis | |||
| Total Debt | 0 | 0 | |
| Cash & Equivalents | 404 | 9,029 | +2134.9% |
| Net Debt | 404 | 9,029 | +2134.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →